In this video, Philip J. Mease, MD, discusses results from the phase 2 ARGO clinical trials of sonelokimab for psoriatic arthritis, presented at the EULAR 2025 Congress.

In this video, Philip J. Mease, MD, discusses the potential for the development of a T-cell engaging antibody.

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

In this video, Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center, in Seattle, discusses results from phase 3b clinical trials of guselkumab.The data, ...

A history of traumatic brain injury was linked to long-term cognitive decline involving speech functions, specifically where ...

Oral upadacitinib may be a promising treatment option for patients with atopic dermatitis-type chronic hand eczema that is ...

Alcon plans to acquire STAAR Surgical through a definitive merger agreement, according to a press release. The acquisition is ...

Disc hemorrhage location was associated with areas of clustered visual field progression in patients with primary open-angle ...

A novel machine learning algorithm has potential to improve detection and treatment of individuals with familial ...

Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...

Direct telephone assistance may help mitigate systemic bias in electronic patient-reported outcome measure follow-up and ...

U.S. News & World Report has named NYU Langone Hospitals as No. 1 in Best Hospitals for pulmonology and lung surgery. In last ...